Ospedale S G Moscati

The medical center is at the forefront of research in Limited-Stage Small-Cell Lung Cancer (LS SCLC), focusing on innovative treatments post-chemoradiotherapy. The center's work in this area aims to enhance progression-free survival through advanced therapeutic options.

• Small-Cell Lung Cancer
• Post-Chemoradiotherapy Treatments
• Progression-Free Survival

By integrating cutting-edge research with clinical practice, the center is pioneering new pathways in lung cancer treatment, offering hope for improved patient outcomes.

Specializing in metastatic colorectal cancer, the center explores the efficacy of various treatment regimens, including intermittent and continuous therapies. The focus is on improving safety, tolerability, and quality of life for patients with RAS/B-RAF wild-type tumors.

• Intermittent vs. Continuous Treatment
• Biomarker-Driven Therapies
• Quality of Life Improvements

The center's research contributes significantly to understanding resistance mechanisms and optimizing therapeutic strategies for colorectal cancer.

In the realm of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, the center is investigating chemo-free strategies that combine targeted therapies with monoclonal antibodies. This approach aims to improve event-free survival and reduce toxicity.

• Chemo-Free Strategies
• Targeted Therapy Combinations
• Event-Free Survival

Through innovative research, the center is redefining treatment paradigms, offering new hope for adult patients with this challenging leukemia subtype.

The center is advancing research in BRCA wild-type advanced ovarian, fallopian tube, and primitive peritoneal cancer through maintenance therapy studies. The focus is on evaluating the efficacy of olaparib and its impact on progression-free survival.

• Maintenance Therapy
• Olaparib Efficacy
• Prognostic Biomarkers

By exploring the biological characteristics of tumors, the center aims to tailor treatments that enhance patient outcomes in these complex cancer types.

Focusing on advanced non-small-cell lung cancer, the center is evaluating combination therapies to improve overall survival in patients with high PD-L1 expression. This research is pivotal in optimizing first-line treatment strategies.

• Combination Therapies
• PD-L1 High Expression
• Overall Survival Improvement

The center's work in this area is crucial for developing personalized treatment plans that address the unique needs of lung cancer patients.